Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
NEKTAR THERAPEUTICS (NKTR)
|
Add to portfolio |
|
|
|
| Price: |
$13.66
| | Metrics |
| OS: |
190.1
|
M
| |
|
|
| Market cap: |
$2.6
|
B
| |
|
|
|
Net cash:
|
$409
|
M
| |
$2.15
|
per share
|
|
EV:
|
$2.19
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 92.1 | 101.9 | 152.9 | 114.6 | 1,193.3 | 307.7 | 165.4 | 230.8 |
| Revenue growth | -9.7% | -33.4% | 33.4% | -90.4% | 287.8% | 86.0% | -28.3% | 15.0% |
| Cost of goods sold | 21.6 | 24.9 | 19.5 | 21.4 | 24.4 | 30.5 | 30.2 | 34.1 |
| Gross profit | 70.4 | 77.0 | 133.4 | 93.2 | 1,168.9 | 277.2 | 135.2 | 196.7 |
| Gross margin | 76.5% | 75.6% | 87.3% | 81.4% | 98.0% | 90.1% | 81.7% | 85.2% |
| Research and development | 218.3 | 400.3 | 408.7 | 434.6 | 399.5 | 268.5 | 203.8 | 182.8 |
| General and administrative | 92.3 | 122.8 | 104.7 | 98.7 | 81.4 | 52.4 | 44.3 | 43.3 |
| EBIT | -376.2 | -446.1 | -425.1 | -440.0 | 687.9 | -59.6 | -112.9 | -29.4 |
| EBIT margin | -408.6% | -437.8% | -278.0% | -383.9% | 57.6% | -19.4% | -68.2% | -12.7% |
| Pre-tax income | -365.0 | -523.3 | -443.9 | -440.1 | 682.7 | -96.1 | -152.6 | -80.7 |
| Income taxes | 3.2 | 0.6 | 0.5 | 0.6 | 1.4 | 0.6 | 0.9 | 0.5 |
| Tax rate | | | | | 0.2% | | | |
| Net income | 0.0 | -523.8 | -444.4 | -440.7 | 681.3 | -96.7 | -153.5 | -81.2 |
| Net margin | 0.0% | -514.0% | -290.6% | -384.5% | 57.1% | -31.4% | -92.8% | -35.2% |
| |
| Diluted EPS | $0.00 | ($2.86) | ($2.49) | ($2.52) | $3.78 | ($0.62) | ($1.10) | ($0.61) |
| Shares outstanding (diluted) | 187.1 | 183.3 | 178.6 | 175.0 | 180.1 | 156.0 | 139.6 | 132.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|